RPRX
Royalty Pharma plc
$60.96
+1.34
(+2.25%)
Mkt Cap
27.14B
Volume
5,786,285
52W Range
35.915-64.38
Sector
Healthcare
Beta
0.41
EPS (TTM)
2.41 USD
P/E Ratio
25.29
Revenue (TTM)
2.54B USD
Rev Growth (5Y)
+2.3%
EPS Growth (5Y)
+12.7%
AlphaVal · Fair Value
What we estimate one share is worth
$78.28
Fair Value
moderate signal
22.1% below fair value
Modeled from cash flows & growth.
AlphaQuality · Grade
How strong & durable the business is
C
Stable Earnings Power
52.2 / 100 composite
Steady, predictable earnings power — graded A–F vs. similar companies.
Company Description
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.38B | 2.26B | 2.35B | 2.24B | 2.29B | 2.12B | 1.81B | 1.79B | 1.60B | 1.88B | 1.65B |
| Net Income | 770.95M | 858.98M | 1.13B | 42.83M | 619.73M | 975.04M | 2.35B | 1.38B | 1.21B | 565.91M | 581.43M |
| EPS | 2.33 | 1.92 | 3.41 | 0.10 | 1.49 | 1.28 | 6.63 | 3.89 | 3.42 | 0.93 | 0.96 |
| Free Cash Flow | 2.49B | 2.77B | 2.99B | 2.14B | 2.02B | 2.03B | 1.67B | 1.62B | 1.42B | N/A | N/A |
| FCF / Share | 5.76 | 6.21 | 6.68 | 4.90 | 4.86 | 5.24 | 4.71 | 4.57 | 4.00 | N/A | N/A |
| Operating CF | 2.49B | 2.77B | 2.99B | 2.14B | 2.02B | 2.03B | 1.67B | 1.62B | 1.42B | N/A | N/A |
| Total Assets | 19.62B | 18.22B | 16.38B | 16.81B | 17.52B | 16.02B | 12.45B | 11.37B | 11.37B | 10.48B | 10.82B |
| Total Debt | 8.95B | 7.61B | 6.14B | 7.12B | 7.10B | 5.82B | 6.24B | 6.52B | 6.80B | 5.90B | 5.99B |
| Cash & Equiv | 618.70M | 929.03M | 477.01M | 1.71B | 1.54B | 1.01B | 246.20M | 1.92B | 1.38B | 1.67B | 1.72B |
| Book Value | 6.48B | 6.95B | 6.53B | 5.63B | 5.78B | 4.82B | 6.11B | 4.49B | 4.46B | 4.45B | 4.68B |
| Return on Equity | 0.12 | 0.12 | 0.17 | 0.01 | 0.11 | 0.20 | 0.38 | 0.31 | 0.27 | 0.13 | 0.12 |
| Metric | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 674.14M | 630.58M | 621.99M | 609.29M | 578.66M | 568.25M | 593.64M | 564.69M | 537.27M | 567.98M | 596.07M | 536.31M |
| Net Income | 17.88M | 295.00M | 214.21M | 288.22M | 30.18M | 238.35M | 208.21M | 543.99M | 102.00M | 4.78M | 494.34M | 72.11M |
| EPS | 0.04 | 0.68 | 0.64 | 1.05 | 0.09 | 0.55 | 0.47 | 1.22 | 0.23 | 0.01 | 1.48 | 0.21 |
| Free Cash Flow | 686.15M | 760.54M | 827.15M | 702.62M | 363.98M | 596.08M | 742.52M | 703.61M | 658.21M | 664.64M | 772.63M | 573.52M |
| FCF / Share | 1.54 | 1.76 | 1.92 | 1.63 | 0.86 | 1.37 | 1.66 | 1.58 | 1.46 | 1.48 | 1.72 | 1.28 |
| Operating CF | 686.15M | 760.54M | 827.15M | 702.62M | 363.98M | 596.08M | 742.52M | 703.61M | 658.21M | 664.64M | 772.63M | 573.52M |
| Total Assets | 19.82B | 19.82B | 19.62B | 19.35B | 18.32B | 17.61B | 18.22B | 18.04B | 17.66B | 16.13B | 16.38B | 15.86B |
| Total Debt | 8.96B | 8.96B | 8.95B | 8.97B | 8.00B | 7.62B | 7.61B | 7.61B | 7.60B | 6.14B | 6.14B | 6.13B |
| Cash & Equiv | 812.00M | 586.39M | 619.00M | 938.94M | 631.91M | 1.09B | 929.03M | 950.05M | 1.76B | 843.00M | 477.01M | 936.45M |
| Book Value | 6.83B | 6.89B | 6.48B | 6.41B | 6.35B | 6.69B | 6.95B | 6.87B | 6.48B | 6.50B | 6.53B | 6.14B |
| Return on Equity | 0.00 | 0.04 | 0.03 | 0.04 | 0.00 | 0.04 | 0.03 | 0.08 | 0.02 | 0.00 | 0.08 | 0.01 |
RPRX News
Royalty Pharma declares fourth quarter 2026 dividend
Royalty Pharma to announce third quarter 2026 financial results on November 4, 2026
Why Royalty Pharma (RPRX) is Poised to Beat Earnings Estimates Again
Eastern Bank Buys 13,843 Shares of Royalty Pharma PLC $RPRX
Royalty Pharma Owns a Piece of 16 Blockbuster Drugs -- Is the Stock a Buy?
Royalty Pharma (NASDAQ:RPRX) Stock: Insider Christopher Hite Sells 100,000 Shares
Royalty Pharma Eyes AI, China Growth While Navigating Biopharma Policy Shifts
Is Buying Royalty Pharma Stock a Safer Way to Bet on Revolution Medicines?
Royalty Pharma plc (RPRX) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Royalty Pharma announces $7.5 million gift to Blood Cancer United to expand Therapy Acceleration Program